# Cerapedics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cerapedics

- Industry: Medical Devices & Equipment
- Headquarters: Westminster, US
- Website: www.cerapedics.com
- Total disclosed funding: $53M
- Latest round: Series C (Feb 18, 2015)
- Investors on record: 4

## About

CeraPedics, Inc. is a pioneering orthopedic company specializing in innovative bone graft solutions that enhance healing and patient outcomes, particularly through their flagship product, the i-FACTOR P-15 Peptide Enhanced Bone Graft.CeraPedics, Inc. focuses on developing orthopedic products aimed at improving bone healing. Founded in 2001 and headquartered in Westminster, US, the company has executed 15 deals.In Q4 2025, Cerapedics Inc. raised an undisclosed amount of venture debt funding from Perceptive Advisors.The CEO of CeraPedics is Valeska Schroeder.CeraPedics specializes in advanced orthopedic solutions centered around their flagship product, the i-FACTOR P-15 Peptide Enhanced Bone Graft. This product is designed to support faster and more effective bone healing for surgical procedures like single-level anterior cervical discectomy and fusion (ACDF). Since its introduction in 2015, i-FACTOR has been widely used by surgeons within various healthcare institutions, addressing bone repair challenges. The company primarily serves hospitals, surgical centers, and orthopedic specialists in the U.S. market, while also extending its reach internationally, emphasizing scientifically backed products that improve patient outcomes through clinical evidence and research.CeraPedics generates revenue through direct sales of the i-FACTOR P-15 Peptide Bone Graft to healthcare providers, including hospitals and surgical practices. These transactions are structured as direct B2B sales, and the pricing reflects the premium nature of their advanced technology and clinical efficacy. Revenue predominantly comes from unit sales of their products, with potential additional income from partnerships and collaborations focused on advancing research and development in spine surgery.

## Funding rounds

- Series C, Feb 18, 2015, $4M — OrbiMed Advisors
- Series C, Nov 26, 2012, $7M — OrbiMed Advisors, NGN Capital, MedImmune Ventures, Henry Crown and Company
- Series C, Jul 12, 2012, $12M — OrbiMed Advisors, NGN Capital
- Series B, Mar 18, 2009, $15M — OrbiMed Advisors, NGN Capital
- Series A, Sep 12, 2007, $7.3M — OrbiMed Advisors
- Series A, Feb 27, 2007, $7.2M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- NGN Capital (https://capitalatlas.ai/funds/ngn-capital) — Series B, Series C
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series C
- Henry Crown and Company — Series C